| Article Access Statistics | | | Viewed | 1790 | | | Printed | 117 | | | Emailed | 0 | | | PDF Downloaded | 219 | | | Comments | [Add] | | |
|
Click on image for details.
|
|
| REVIEW ARTICLE |
|
| Year : 1994 | Volume
: 26
| Issue : 2 | Page : 94-107 |
Therapeutic potentials of 5-HT receptor modulators
YK Gupta, A Prakash
Correspondence Address:
Y K Gupta
 Source of Support: None, Conflict of Interest: None  | Check |
5-hydroxytryptamine (5-HT) has become one of the most investigated and complex biogenic amines. The main receptors and their subtypes e.g. 5-HTI (5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F ), 5-HT (5-HT2A, 5-HT2B and 5-HT2C) , 5-HT3 and 5-HT4 have been identified. Additional receptors e.g., 5-HT5, 5-HT6 and subtypes of 5-HT3 have been proposed. Specific drugs which are capable of either selectively stimulating or inhibiting these receptor subtypes are being designed. This has generated great interest in exploring the therapeutic potentials of 5-HT receptor modulators in a variety of disease conditions. Conditions where 5-HT receptor modulators have established their use with distinct efficacy and advantages include migraine, anxiety and cancer therapy-induced vomiting by cytotoxic drugs and radiation. Based on the knowledge of their role in the pathophysiology of diseases, findings of animal experiments or early clinical trials, these agents have shown promise in ameliorating a number of ailments and symptoms. The potential of 5-HT receptor modulators in pain, schizophrenia, depression, parkinsonism, drug abuse, aggression, irritable bowel syndrome, carcinoid syndrome, dyspepsia, non-cardiac chest pain, gastroesophageal reflux disease, diabetic gastroparesis, hypertension, peripheral vascular diseases and glaucoma have been discussed in this article.
[PDF]*
|
